IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade
- PMID: 9217189
- DOI: 10.1046/j.1365-2141.1997.1112925.x
IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade
Abstract
Acute graft-versus-host disease (GVHD) severity is graded by pattern of organ involvement and clinical performance status using a system introduced by Glucksberg and colleagues 21 years ago. We examined how well Glucksberg grade predicted transplant outcome and constructed a Severity Index not requiring subjective assessment of performance in 2881 adults receiving an HLA-identical sibling T-cell-depleted (n = 752) or non-T-cell-depleted (n = 2129) bone marrow transplant for leukaemia between 1986 and 1992. Relative risks (RR) of relapse, treatment-related mortality (TRM) and treatment failure (TF) (relapse or death) were calculated for patients with (Glucksberg Grade I, II or III/IV acute (GVHD) versus those without acute GVHD and for patients with distinct patterns of organ involvement regardless of Glucksberg grade. Using data for non-T-cell-depleted transplants, a Severity Index was developed grouping patients with patterns of organ involvement associated with similar risks of TRM and TF. Higher Glucksberg grade predicted poorer outcome; however, patients with the same grade but different patterns of skin, liver or gut involvement often had significantly different outcomes. The revised Severity Index groups patients in four categories, A-D. Compared to patients without acute GVHD, RRs (95% confidence interval) of TF were 0.85 (0.69, 1.05) for patients with Index A, 1.21 (1.02, 1.43) with B, 2.19 (1.78, 2.71) with C, and 5.69 (4.57, 7.08) with D. Prognostic utility of the Index was tested in patients receiving T-cell-depleted transplants; similar RRs of TF were observed. An acute GVHD Severity Index is proposed to enhance design and interpretation of clinical trials in the current era of allogeneic blood and bone marrow transplantation.
Similar articles
-
Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry.Bone Marrow Transplant. 1999 Aug;24(3):283-7. doi: 10.1038/sj.bmt.1701899. Bone Marrow Transplant. 1999. PMID: 10455367
-
A multivariate approach for assessing severity of acute graft-versus-host disease in bone marrow transplantation.Stat Med. 1999 Feb 28;18(4):423-40. doi: 10.1002/(sici)1097-0258(19990228)18:4<423::aid-sim27>3.0.co;2-e. Stat Med. 1999. PMID: 10070684
-
Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review.Biol Blood Marrow Transplant. 2003 Aug;9(8):512-8. doi: 10.1016/s1083-8791(03)00162-9. Biol Blood Marrow Transplant. 2003. PMID: 12931120
-
Grading acute graft-versus-host disease: time to reconsider.Pediatr Transplant. 2015 May;19(3):252-4. doi: 10.1111/petr.12433. Epub 2015 Jan 20. Pediatr Transplant. 2015. PMID: 25599820 Review.
-
Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.Dan Med Bull. 2002 May;49(2):89-108. Dan Med Bull. 2002. PMID: 12064093 Review.
Cited by
-
Corrigendum: Perspective: A Framework to Screen Pediatric and Adolescent Hematopoietic Cellular Therapy Patients for Organ Dysfunction: Time for a Multi-Disciplinary and Longitudinal Approach.Front Oncol. 2021 Apr 23;11:679526. doi: 10.3389/fonc.2021.679526. eCollection 2021. Front Oncol. 2021. PMID: 33968787 Free PMC article.
-
What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score.Br J Haematol. 2012 Jun;157(6):732-41. doi: 10.1111/j.1365-2141.2012.09114.x. Epub 2012 Apr 6. Br J Haematol. 2012. PMID: 22486355 Free PMC article. Clinical Trial.
-
Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.Blood Adv. 2024 Feb 13;8(3):581-590. doi: 10.1182/bloodadvances.2023011622. Blood Adv. 2024. PMID: 38052043 Free PMC article.
-
Haploidentical hematopoietic stem cell transplantation without total body irradiation for pediatric acute leukemia: a single-center experience.Onco Targets Ther. 2016 May 2;9:2557-63. doi: 10.2147/OTT.S102286. eCollection 2016. Onco Targets Ther. 2016. PMID: 27217774 Free PMC article.
-
Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML.Bone Marrow Transplant. 2016 Dec;51(12):1561-1564. doi: 10.1038/bmt.2016.217. Epub 2016 Aug 15. Bone Marrow Transplant. 2016. PMID: 27526282
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous